查看“Nectin-4”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>[[Nectin-4]]</strong>（又称<strong>[[PVRL4]]</strong>）是一种属于[[I型跨膜糖蛋白]]家族的[[细胞粘附分子]]。它主要介导[[细胞-细胞]]间的粘附，并在胚胎发育、组织构建中发挥关键作用。在正常生理条件下，[[Nectin-4]]在成人体内的表达水平极低且分布局限（主要在[[胎盘]]、[[皮肤]]及[[乳腺]]导管中），但在多种上皮源性恶性肿瘤——尤其是<strong>[[尿路上皮癌]]</strong>、<strong>[[乳腺癌]]</strong>和<strong>[[胰腺癌]]</strong>中高度过表达。这一特异性表达谱使其成为<strong>[[抗体偶联药物]]</strong>（<strong>[[ADC]]</strong>）研发的核心靶点。目前，以<strong>[[恩诺单抗]]</strong>（[[Padcev]]）为代表的靶向药物已彻底改写了晚期[[膀胱癌]]的治疗结局。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #ffffff 0%, #e0f2fe 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[Nectin-4]]</div>
            <div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">[[PVRL4]] · 关键[[ADC]]靶点 · 点击展开</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 20px; text-align: center; background-color: #f8fafc;">
                <div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;">
                    <div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[Nectin-4]]跨膜蛋白结构模型</div>
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">染色体位置：1q23.3</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">[[Entrez]]ID</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">81607</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]ID</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">19668</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">Q96NY8</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">所属家族</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[免疫球蛋白超家族]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约66kDa</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">相关癌种</th>
                    <td style="padding: 12px; color: #0f172a;">[[尿路上皮癌]]•[[乳腺癌]]</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子结构与生物学机制</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        [[Nectin-4]]不仅是一种物理性的连接蛋白，更参与了调控肿瘤细胞[[迁移]]和[[侵袭]]的复杂信号网络：
    </p>
    
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>结构组成：</strong>[[Nectin-4]]由三个[[Ig样]]胞外结构域、一个[[跨膜螺旋]]及一个胞内[[C-末端]]组成。其胞外域负责与[[Nectin-1]]或[[Nectin-4]]自身发生[[顺式]]或[[反式二聚化]]。</li>
        <li style="margin-bottom: 12px;"><strong>信号转导激活：</strong>通过其胞内结构域的[[Afadin]]结合位点，[[Nectin-4]]能够激活<strong>[[PI3K/AKT]]</strong>和<strong>[[Ras/MAPK]]</strong>通路，促进肿瘤细胞的生存和[[有丝分裂]]。</li>
        <li style="margin-bottom: 12px;"><strong>肿瘤转移驱动：</strong>在[[乳腺癌]]中，[[Nectin-4]]的过表达通过激活[[Rac1]]信号诱导[[上皮-间质转化]]（[[EMT]]），从而增强肿瘤细胞的[[远处转移]]能力。</li>
        <li style="margin-bottom: 12px;"><strong>配体功能：</strong>由于其具有较好的[[内吞]]速率，这使得针对[[Nectin-4]]设计的[[ADC]]能够高效地将细胞毒性载荷递送至内体及[[溶酶体]]系统。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床意义与靶向药物矩阵</h2>

    <div style="overflow-x: auto; margin: 25px auto; width: 95%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;">
            <tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">药物/技术</th>
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">作用性质</th>
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">当前临床价值与适应症</th>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[恩诺单抗]] (EV)</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">[[ADC]] (靶向Nectin-4)</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">全球首个该靶点药物，确立了晚期[[尿路上皮癌]]一线及后线治疗地位。</td>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[Nectin-4 IHC]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">[[伴随诊断]] / [[IHC]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">用于筛选多种实体瘤（如[[肺癌]]、[[胰腺癌]]）中获益人群的关键指标。</td>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[第二代Nectin-4 ADC]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">临床在研管线</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">旨在通过更换[[载荷]]（如[[拓扑异构酶抑制剂]]）克服[[MMAE]]耐药。</td>
            </tr>
        </table>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：靶点特异性毒性管理</h2>
    <p style="margin: 15px 0; text-align: justify;">
        靶向[[Nectin-4]]的ADC药物应用中，其特异性的毒性管理是临床工作的核心重点：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>[[皮肤毒性]]风险：</strong>由于正常皮肤基底层亦存在低水平[[Nectin-4]]表达，治疗中极易出现[[皮疹]]。临床中需严密监测，谨防发生重症[[大疱性皮炎]]（[[SJS]]/[[TEN]]）。</li>
        <li style="margin-bottom: 12px;"><strong>[[高血糖]]监测：</strong>[[恩诺单抗]]等药物与胰岛功能的潜在关联需引起警惕，糖尿病患者用药前需评估[[糖化血红蛋白]]水平。</li>
        <li style="margin-bottom: 12px;"><strong>[[联合免疫治疗]]：</strong>在晚期[[膀胱癌]]中，推荐[[Nectin-4 ADC]]与[[PD-1单抗]]联用。该策略通过协同效应极大提升了疾病的[[客观缓解率]]([[ORR]])。</li>
        <li style="margin-bottom: 12px;"><strong>[[组织活检]]必要性：</strong>虽然[[Nectin-4]]在UC中广泛表达，但在复发[[转移性乳腺癌]]或[[胰腺癌]]中，建议行[[IHC]]检测以明确表达丰度。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2>
    <div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;">
        <ul style="margin: 0; padding-left: 20px; color: #334155;">
            <li style="margin-bottom: 8px;"><strong>[[PVRL4]]：</strong>[[Nectin-4]]的官方基因名称。</li>
            <li style="margin-bottom: 8px;"><strong>[[恩诺单抗]] (Padcev)：</strong>目前全球最成功的针对[[Nectin-4]]靶点的ADC药物。</li>
            <li style="margin-bottom: 8px;"><strong>[[脊髓灰质炎病毒]]受体样蛋白：</strong>[[Nectin]]家族的原始命名来源，反映了其演化背景。</li>
            <li style="margin-bottom: 8px;"><strong>[[旁观者效应]]：</strong>指载药释放后杀伤周围低表达细胞的能力，是ADC药物疗效的关键因素。</li>
        </ul>
    </div>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Challita-Eid PM, et al. (2016).</strong> <em>Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.</em> <strong>[[Cancer Research]]</strong>.[Academic Review]<br>
            <span style="color: #475569;">[权威点评]：该项基础研究揭示了Nectin-4作为癌症精准打击靶点的卓越潜力。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>Powles T, et al. (2024).</strong> <em>Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer (EV-302).</em> <strong>[[The New England Journal of Medicine]]</strong>.<br>
            <span style="color: #475569;">[核心价值]：EV-302研究证实了靶向Nectin-4 ADC在一线治疗中的划时代价值。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            [[Nectin-4]] ([[PVRL4]]) 诊疗生态 · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td>
                <td style="padding: 10px 15px; color: #334155;">[[Afadin]]•[[PI3K]]•[[AKT]]•[[TROP2]]•[[EGFR]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联人群</td>
                <td style="padding: 10px 15px; color: #334155;">[[晚期膀胱癌]]•[[三阴性乳腺癌]]•[[经治胰腺癌]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td>
                <td style="padding: 10px 15px; color: #334155;">[[Seagen]]•[[辉瑞]]•[[安斯泰来]]•[[NMPA]]•[[FDA]]</td>
            </tr>
            <tr>
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究前沿</td>
                <td style="padding: 10px 15px; color: #334155;">[[双抗ADC研发(如Nectin-4 x TROP2)]]•[[克服MMAE耐药机制研究]]•[[围手术期新辅助应用探索]]</td>
            </tr>
        </table>
    </div>

</div>